Skip to main content
Grant Details

Grant Number: 5R01CA196873-05 Interpret this number
Primary Investigator: Joseph, Anne
Organization: University Of Minnesota
Project Title: Adaptive Interventions for Smoking Cessation in Lung Cancer Screening Programs
Fiscal Year: 2019


 DESCRIPTION (provided by applicant): Clinical trials have demonstrated the efficacy of behavioral, pharmacological, and combination treatment strategies for smoking cessation, but these treatments yield frustratingly low rates of long-term abstinence. There is emerging consensus that tobacco dependence is a chronic condition, but chronic disease management models for smoking cessation are under-developed. Practitioners have scant guidance regarding how to manage cessation treatment over time. Adaptive interventions are well-suited to conditions like tobacco dependence where patients vary in response to treatment, effectiveness of treatment may change over time, and relapse is common. Sequential, multiple assignment, randomized trials (SMART) are a novel method to rigorously compare different adaptive intervention effects. We propose a SMART to identify the optimal sequence of smoking cessation treatments for smokers who respond both incompletely (any smoking after quit date) and completely to first-line treatment (8 weeks of counseling with nicotine replacement therapy), conducted in the setting of lung cancer screening programs. The U.S. Preventive Services Task Force recommendation to screen persons at high risk for lung cancer (based on age and smoking history) creates a clinical imperative to establish efficient and effective systems to trea smokers on a large scale. Our team recently demonstrated the efficacy of one adaptive intervention for smoking cessation, Tobacco Longitudinal Care (TLC), that provides counseling and nicotine replacement therapy for one year, incorporating plans for smokers who have difficulty quitting or quit and relapse. In this proposal, our primary aim is to test whether the beneficial effect of adaptive TLC treatment can be augmented by the strategic addition of pharmacist-assisted access to the prescription medications bupropion or varenicline (Medication Therapy Management). Current smokers who are eligible for lung cancer screening will be identified using the electronic medical record at the University of Minnesota and Minneapolis VA (N=1000). All participants will receive 8 weeks of evidence-based first-line smoking cessation treatment. Participants will be eligible for three potential randomizations during one year of smoking intervention: 1) to timing of identifying early response to treatment at 4 vs. 8 weeks (all participants), 2) to telephone-based tobacco longitudinal care (TLC) vs. TLC plus pharmacist-administered Medication Therapy Management (incomplete responders to first-line treatment, Primary Aim), and 3) to monthly TLC contact vs. quarterly TLC contact (complete responders to first-line treatment, Secondary Aim). The primary outcome will be 6 months of prolonged abstinence measured 18 months after the beginning of treatment. Analyses for secondary and exploratory aims will include potential moderators such as amount of response to treatment and lung cancer screening results. Results from this SMART will inform decisions regarding the intensity and sequence of smoking cessation treatments for millions of current smokers who will undergo annual low-dose CT scanning for lung cancer.


Optimizing Longitudinal Tobacco Cessation Treatment in Lung Cancer Screening: A Sequential, Multiple Assignment, Randomized Trial.
Authors: Fu S.S. , Rothman A.J. , Vock D.M. , Lindgren B.R. , Almirall D. , Begnaud A. , Melzer A.C. , Schertz K.L. , Branson M. , Haynes D. , et al. .
Source: JAMA network open, 2023-08-01; 6(8), p. e2329903.
EPub date: 2023-08-01.
PMID: 37615989
Related Citations

Design considerations and analytical framework for reliably identifying a beneficial individualized treatment rule.
Authors: Cain C.H. , Murray T.A. , Rudser K.D. , Rothman A.J. , Melzer A.C. , Joseph A.M. , Vock D.M. .
Source: Contemporary clinical trials, 2022 Dec; 123, p. 106951.
EPub date: 2022-10-12.
PMID: 36241146
Related Citations

Predictors of Enrollment of Older Smokers in Six Smoking Cessation Trials in the Lung Cancer Screening Setting: The Smoking Cessation at Lung Examination (SCALE) Collaboration.
Authors: Eyestone E. , Williams R.M. , Luta G. , Kim E. , Toll B.A. , Rojewski A. , Neil J. , Cinciripini P.M. , Cordon M. , Foley K. , et al. .
Source: Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2021-11-05; 23(12), p. 2037-2046.
PMID: 34077535
Related Citations

Impact of the COVID-19 pandemic on telehealth research in cancer prevention and care: A call to sustain telehealth advances.
Authors: Park E.R. , Chiles C. , Cinciripini P.M. , Foley K.L. , Fucito L.M. , Haas J.S. , Joseph A.M. , Ostroff J.S. , Rigotti N.A. , Shelley D.R. , et al. .
Source: Cancer, 2021-02-01; 127(3), p. 334-338.
EPub date: 2020-10-13.
PMID: 33048350
Related Citations

Self-reported exercise capacity among current smokers eligible for lung cancer screening: Distribution and association with key comorbidities.
Authors: Melzer A.C. , Begnaud A. , Lindgren B.R. , Schertz K. , Fu S.S. , Vock D.M. , Rothman A.J. , Joseph A.M. .
Source: Cancer treatment and research communications, 2021; 28, p. 100443.
EPub date: 2021-07-31.
PMID: 34371253
Related Citations

Lung Cancer Screening and Smoking Cessation Clinical Trials. SCALE (Smoking Cessation within the Context of Lung Cancer Screening) Collaboration.
Authors: Joseph A.M. , Rothman A.J. , Almirall D. , Begnaud A. , Chiles C. , Cinciripini P.M. , Fu S.S. , Graham A.L. , Lindgren B.R. , Melzer A.C. , et al. .
Source: American journal of respiratory and critical care medicine, 2018-01-15; 197(2), p. 172-182.
PMID: 28977754
Related Citations

Program for lung cancer screening and tobacco cessation: Study protocol of a sequential, multiple assignment, randomized trial.
Authors: Fu S.S. , Rothman A.J. , Vock D.M. , Lindgren B. , Almirall D. , Begnaud A. , Melzer A. , Schertz K. , Glaeser S. , Hammett P. , et al. .
Source: Contemporary clinical trials, 2017 Sep; 60, p. 86-95.
EPub date: 2017-07-04.
PMID: 28687349
Related Citations

Back to Top